The 3Rs framework — Replace, Reduce, Refine — has guided animal testing ethics for over 60 years. In 2025, accelerating technology, legislative change, and shifting regulatory frameworks are transforming what the 3Rs mean in practice.
William Russell and Rex Burch introduced the 3Rs framework in "The Principles of Humane Experimental Technique" in 1959. Despite its age, the framework remains the dominant conceptual approach to animal use in research globally:
Use methods that avoid or replace the use of animals. This includes: complete replacement (no animals used) through cell cultures, computer models, and in vitro systems; and relative replacement (using less sentient organisms instead of mammals, e.g., invertebrates instead of rodents, zebrafish instead of mammals).
Use methods that minimize the number of animals used while obtaining the same amount of information. Includes: better experimental design (statistical power analysis to avoid both over- and under-powered studies), data sharing to avoid repetition, and using existing data where possible.
Use methods that minimize pain, suffering, distress, and lasting harm for animals that must be used. Includes: improved housing conditions and enrichment, better analgesia and anesthesia, more humane endpoints (ending experiments before animals are in maximum distress), and improved handling and care.
Global data is incomplete, but key figures:
Mice and rats constitute approximately 75-80% of all vertebrate animals used globally. Other major species include fish, birds, rabbits, guinea pigs, pigs, dogs, primates, and horses.
The most significant development in animal testing over the past decade is the rapid advancement of New Approach Methods — laboratory tools that can replace or substantially reduce animal use:
Microfluidic devices containing living human cells that replicate the microarchitecture and function of human organs. Developed significantly at the Wyss Institute (Harvard), these systems can model lung, liver, kidney, intestine, and other organs with greater human relevance than animal models. Key developments in 2025:
3D tissue cultures grown from stem cells that self-organize into mini-organs with structural and functional features of real organs. Brain organoids, gut organoids, and others are increasingly replacing animal models in early-stage research. Advances in vascularization and long-term culture are extending their applicability.
Machine learning models can now predict chemical toxicity, drug metabolism, and pharmacological effects from molecular structure with increasing accuracy. The FDA Modernization Act 2.0 (US, 2022) explicitly allowed computational and in vitro data as alternatives to animal testing for drug approval — a landmark regulatory shift.
High-throughput screening using human cell lines, primary cells, and induced pluripotent stem cells (iPSCs) allows toxicity testing at massive scale. EPA's ToxCast program has screened thousands of chemicals using human cell-based assays, generating data that reduces animal testing needs.
| Jurisdiction | Development | Significance |
|---|---|---|
| USA | FDA Modernization Act 2.0 (2022) | Removes mandatory animal testing for drugs |
| EU | Strategy to phase out animal testing for regulatory purposes (ongoing) | Multi-stakeholder roadmap for NAM transition |
| EU | Cosmetics Regulation ban on animal testing (2013, fully implemented) | First major sector-wide ban — now extended |
| UK | CRACK IT Challenges and NC3Rs funding for alternative development | Leading funder of 3Rs research |
| Netherlands | Target to be a "pioneer country" in animal-free research by 2025 | Government-wide transition program |
While replacement advances, significant work continues to improve welfare for animals still used in research:
NHP research is increasingly controversial and tightly regulated. Key welfare improvements in facilities that do use NHPs: